Lutetium-177 labelled edotreotide

镥[177Lu]依多曲肽

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameLutetium-177 labelled edotreotide
Drug Alias Name镥[177Lu]依多曲肽177Lu-DOTATOCPeptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide177Lu-edotreotide PRRTn.c.a.177Lu-Edotreotide +[10] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIonising radiation emittersSomatostatin receptor 2 binders
TargetsSomatostatin receptor 2
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Neuroendocrine Carcinoma of LungGastroenteropancreatic neuroendocrine tumor +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesUniversitaetsspitals BaselItm Solucin Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesNtp Radioisotopes Soc LtdITM Oncologics GmbHDuchemBio Co Ltd +[5] 
Inactive CompaniesUniversity Of Warmia And Mazury In Olsztyn
Active IndicationsPancreatic neuroendocrine tumors (pNET)Neuroendocrine Carcinoma of LungGastroenteropancreatic neuroendocrine tumor +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A